COMPARATIVE ANALYSIS OF THE COURSE OF THE DISEASE OF COVID-19 IN PATIENTS NOT VACCINATED AND VACCINATED WITH PFIZER-BIONTECH OR MODERNA
DOI:
https://doi.org/10.11603/1681-2786.2023.2.14029Keywords:
vaccine, Pfizer-BioNTech, Moderna, health, COVID-19, complicationsAbstract
Purpose: to evaluate the effect of vaccination with mRNA vaccines on the severity of the course for the disease of COVID-19, the level of hospitalization and distribution of virus.
Materials and Methods. The results of questionnaires and surveys of people were used in the study. The methods of comparative, systemic analyses were used.
Results. Our study included 1038 participants, of which 576 were vaccinated and 462 were unvaccinated. Among the vaccinated people, 21 had pneumonia, 18 had hypercoagulation, 34 had multiple organ failure, and 26 had post-COVID-19 syndrome.
Among unvaccinated people, 163 had pneumonia, 118 had hypercoagulation, 147 had multiple organ failure, and 197 had post-COVID-19 syndrome.
Conclusions. The effectiveness of the Pfizer-BioNTech vaccine had a major impact on the course of the pandemic. Vaccines stimulate the immune system and provoke the creation of highly specialized antibodies and the recruitment of T-killers, which counteract the massive replication of the virus, and therefore facilitate the clinical course of the disease and the presence of symptoms. In addition, it helped reduce transmission rates, providing protection against asymptomatic infections. This allowed countries to begin rebuilding their economies and protect people from serious complications of the disease.
References
Karnik, M., Beeraka, N.M., Uthaiah, C.A., Nataraj, S.M., Bettadapura, A.D.S., Aliev, G., & Madhunapantula, S.V. (2021). A Review on SARS-CoV-2-Induced Neuroinflammation, Neurodevelopmental Complications, and Recent Updates on the Vaccine Development. Molecular Neurobiology. DOI 10.1007/s12035-021-02399-6. DOI: https://doi.org/10.1007/s12035-021-02399-6
Bourgonje, A.R., Abdulle, A.E., Timens, W., Hillebrands, J., Navis, G.J., Gordijn, S.J., … Goor, H. (2020). Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). The Journal of Pathology, 251(3), 228-248. DOI 10.1002/path.5471. DOI: https://doi.org/10.1002/path.5471
Zhang, H., Penninger, J.M., Li, Y., Zhong, N., & Slutsky, A.S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine, 46(4), 586-590. DOI 10.1007/s00134-020-05985-9. DOI: https://doi.org/10.1007/s00134-020-05985-9
Mazza, M.G., De Lorenzo, R., Conte, C., Poletti, S., Vai, B., Bollettini, I., … Benedetti, F. (2020). Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain, Behavior, and Immunity, 89, 594-600. DOI 10.1016/j.bbi.2020.07.037. DOI: https://doi.org/10.1016/j.bbi.2020.07.037
Soy, M., Keser, G., Atagündüz, P., Tabak, F., Atagündüz, I., & Kayhan, S. (2020). Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clinical Rheumatology, 39(7), 2085-2094. DOI 10.1007/s10067-020-05190-5. DOI: https://doi.org/10.1007/s10067-020-05190-5
Dal-Ré, R. (2021). US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine. Vaccine, 39(8), 1180-1182. DOI 10.1016/j.vaccine.2021.01.050. DOI: https://doi.org/10.1016/j.vaccine.2021.01.050
Tabassum, A., Iqbal, M.S., Sultan, S., Alhuthali, R.A., Alshubaili, D.I., Sayyam, R.S., … Arbaeen, A.F. (2022). Dysregulated Bradykinin: Mystery in the Pathogenesis of COVID-19. Mediators of Inflammation, 2022, 1-8. DOI 10.1155/2022/7423537. DOI: https://doi.org/10.1155/2022/7423537
Graña, C., Ghosn, L., Evrenoglou, T., Jarde, A., Minozzi, S., Bergman, H., ... Boutron, I. (2022). Efficacy and safety of COVID-19 vaccines. Cochrane Database of Systematic Reviews, 2022(12). DOI 10.1002/14651858.cd015477. DOI: https://doi.org/10.1002/14651858.CD015477
Explorons le code source du vaccin BioNTech / Pfizer contre le SARS-CoV-2. Retrieved from: https://renaudguerin.net/posts/explorons-le-code-source-du-vaccin-biontech-pfizer-sars-cov-2/.
Perico, L., Benigni, A., Casiraghi, F., Ng, L.F.P., Renia, L., & Remuzzi, G. (2020). Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nature Reviews Nephrology, 17(1), 46-64. DOI 10.1038/s41581-020-00357-4. DOI: https://doi.org/10.1038/s41581-020-00357-4
Iwasaki, A., & Omer, S.B. (2020). Why and How Vaccines Work. Cell, 183(2), 290-295. DOI 10.1016/j.cell.2020.09.040. DOI: https://doi.org/10.1016/j.cell.2020.09.040
Katella, K. (2021). Comparing the COVID-19 Vaccines: How Are They Different? Dental News, 28(1), 8-17. DOI 10.12816/0059056. DOI: https://doi.org/10.12816/0059056
Cantuti-Castelvetri, L., Ojha, R., Pedro, L.D., Djannatian, M., Franz, J., Kuivanen, S., … Simons, M. (2020). Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science, 370(6518), 856-860. DOI 10.1126/science.abd2985. DOI: https://doi.org/10.1126/science.abd2985
Saciuk, Y., Kertes, J., Mandel, M., Hemo, B., Shamir Stein, N., & Ekka Zohar, A. (2022). Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel. Preventive Medicine, 155, 106947. DOI 10.1016/j.ypmed.2021.106947. DOI: https://doi.org/10.1016/j.ypmed.2021.106947
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., … Pöhlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181(2), 271-280.e8. DOI 10.1016/j.cell.2020.02.052. DOI: https://doi.org/10.1016/j.cell.2020.02.052
Semeraro, N., & Colucci, M. (2021). The prothrombotic state associated with sars-cov-2 infection: pathophysiological aspects. Mediterranean Journal of Hematology and Infectious Diseases, 13(1). DOI 10.4084/mjhid.2021.045. DOI: https://doi.org/10.4084/MJHID.2021.045
Okba, N.M.A., Müller, M.A., Li, W., Wang, C., GeurtsvanKessel, C.H., Corman, V.M., … Haagmans, B.L. (2020). Severe acute respiratory syndrome coronavirus 2−specific antibody responses in coronavirus disease patients. Emerging Infectious Diseases, 26(7), 1478-1488. DOI 10.3201/eid2607.200841. DOI: https://doi.org/10.3201/eid2607.200841
Qi, F., Qian, S., Zhang, S., & Zhang, Z. (2020). Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochemical and Biophysical Research Communications, 526(1), 135-140. DOI 10.1016/j.bbrc.2020.03.044. DOI: https://doi.org/10.1016/j.bbrc.2020.03.044
Xu, A., Hong, B., Lou, F., Wang, S., Li, W., Shafqat, A., … Fan, H. (2022). Sub-lineages of the SARS-CoV-2 Omicron variants: Characteristics and prevention. MedComm, 3(3). DOI 10.1002/mco2.172. DOI: https://doi.org/10.1002/mco2.172
Katawa, G., Tchopba, C.N., Tchadié, P.E., Simfele, C.H., Kamassa, E.H., Amessoudji, M.O., … Karou, S.D. (2021). Systematic Review on COVID-19 Vaccines: Comparative Study of AstraZeneca, Pfizer-BioNTech, Sputnik V, Johnson & Johnson, Moderna and Corona Vac. International Journal of Innovative Research in Medical Science, 6(11), 784-794. DOI 10.23958/ijirms/vol06-i11/1250. DOI: https://doi.org/10.23958/ijirms/vol06-i11/1250
Verdecchia, P., Cavallini, C., Spanevello, A., & Angeli, F. (2020). The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. European Journal of Internal Medicine, 76, 14-20. DOI 10.1016/j.ejim.2020.04.037. DOI: https://doi.org/10.1016/j.ejim.2020.04.037
Veluswamy, P., Wacker, M., Stavridis, D., Reichel, T., Schmidt, H., Scherner, M., … Michels, G. (2021). The SARS-CoV-2/Receptor Axis in Heart and Blood Vessels: A Crisp Update on COVID-19 Disease with Cardiovascular Complications. Viruses, 13(7), 1346. DOI 10.3390/v13071346. DOI: https://doi.org/10.3390/v13071346
Wilson, B., & Geetha, K.M. (2022). Lipid nanoparticles in the development of mRNA vaccines for COVID-19. Journal of Drug Delivery Science and Technology, 74, 103553. DOI 10.1016/j.jddst.2022.103553. DOI: https://doi.org/10.1016/j.jddst.2022.103553
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Bulletin of Social Hygiene and Health Protection Organization of Ukraine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
1. The authors reserve the right to authorship of the work and pass the journal right of first publication of this work is licensed under a Creative Commons Attribution License, which allows others to freely distribute the work published with reference to the authors of the original work and the first publication of this magazine.
2. Authors are entitled to enter into a separate agreement on additional non-exclusive distribution of work in the form in which it was published in the magazine (eg work place in the electronic repository institution or publish monographs in part), provided that the reference to the first publication of this magazine.
3. Policy magazine allows and encourages authors placement on the Internet (eg, in storage facilities or on personal websites) manuscript of how to submit the manuscript to the editor and during his editorial processing, since it contributes to productive scientific discussion and positive impact on the efficiency and dynamics of citing published work (see. The Effect of Open Access).
